John Winhusen, University of Cincinnati Semaglutide for Helping Opioid Recovery (SHORE) Status: Development Brigham and Womens 12week pilot, doubleblind, placebocontrolled, randomized trial to evaluate semaglutide in individuals with opioid use disorder who are newly initiating buprenorphine
The NOMs inter- and intra-assay coefficient variations were 6.9 and 5.3%, respectively, with assay sensitivity of 0.225 mol/l in nitrites form ( Assessment of TAC was done using commercial kits (total antioxidant capacity, Bio-diagnostic, Dokki, Egypt) spectrophotometrically at a wavelength of 505 nm, based on a previous study ( via reactive oxygen species (ROS) generated from Fenton's reaction ( Ultrasound Examination During all the studied time points, sonographic measurements including pulsed-wave Doppler of the right and left supratesticular arteries (STAs) and TE were carried out by the same investigator
I love how he takes the emotion out of nutrition without taking the humanity out of it, because it's one thing to read studies and another to actually live this stuff day in and day out
Research Background & Mechanistic Focus Current research use centers on single-pathway incretin receptor signaling and comparative peptide-pathway models, comparative presentation or formulation behavior where applicable, and controlled experimental models designed to evaluate compound-specific signaling activity within non-clinical laboratory systems